Risk of tuberculosis is increased in Behçet's Disease compared to other rheumatological disorders after anti-TNFα treatments: A case series and review of the literature

Abstract

Background/aim: Tumor necrosis factor-alfa (TNF-α) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases and also shown to be effective in Behçet’s disease (BD) patients with major organ involvement. In this study, we aimed to re-evaluate the incidence of tuberculosis (TB) infection after anti-TNFα treatments and to reveal the risk of TB in BD.

Methods: Data of patients who received anti-TNFα treatment between 2005 and 2018 were assessed retrospectively. Demographic features, TNF-α antagonist type/treatment time, Tuberculosis skin test (TST) and QuantiFERON results, isoniazid prophylaxis status, and concomitant corticosteroid (CS) treatments were collected.

Results: A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-α antagonist for a median of 33 months (Q1:12, Q3:62). Thirteen (1%) patients developed TB during the follow-up period. Within 13 TB-positive patients, 7 of them had pulmonary, and 7 had extrapulmonary TB. Although, the median time of (month) TNF-α antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p=0.47). Similarly, TB-positive patients were treated with CSs more than TB-negative patients (80% vs. 60%). Time from the initiation of TNF-α antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). There was a statistically significant increase of TB development in BD patients than non-BD
patients after TNF-α antagonists (7.5% vs. 0.8%, respectively, p=0.007). When we combined our patients with the other series from Turkey, among 12928 patients who received TNF-α antagonists, TB was positive in 12 (3.9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p<0.00001).

**Conclusion:** Our results suggest a higher frequency of TB infections in BD patients with TNF-α antagonists. As biologic agents are increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented.

**Key-words:** Behçet’s disease, TNF-α antagonists, tuberculosis

1. **Introduction**

Tumor necrosis factor-alfa (TNF-α) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). In recent years, experience with these agents has also increased in other immune rheumatological diseases. In Behçet’s disease (BD), a multi-systemic inflammatory disorder, TNF-α antagonists are also shown to be effective in patients with major organ involvement, refractory to conventional immunosuppressives (IS) [1].

The risk of infections is shown to be increased with the use of TNF-α antagonists as a significant side effect [2]. The enhanced risk of mycobacterial infections is especially important in countries with still an elevated prevalence of tuberculosis (TB). In a multicenter large cohort from Turkey, it was previously observed that patients with BD
are more likely to develop TB after anti-TNFα treatments compared to other rheumatic
diseases [3]. The underlying mechanism of this observation may be related to factors
unique to BD, such as genetics, immune mechanisms, or socio-economic status, as well
as concomitant treatment with high dose corticosteroid (CS) and immunosuppressive
therapies [4, 5].

In this study, we aimed to re-evaluate the incidence of TB infection after anti-TNFα
treatments for rheumatic diseases and to reveal the risk of TB according to the
rheumatologic diagnosis, particularly BD. Factors associated with this risk are also
assessed.

2. Methods

2.1. Patients and Data collection

The data of 1277 patients who received TNF-α antagonists between 2005 and 2018 at
Marmara University, School of Medicine, Rheumatology Outpatient Clinics, were
assessed retrospectively. Patients had to have an inflammatory rheumatic disease treated
with one of the TNF-α antagonists (Adalimumab, Infliximab, Etanercept, Golimumab,
and Certolizumab Pegol) to be included in the study. Follow-up data were collected
from standard patient report forms and medical chart reviews: demographic features,
TNF-α antagonist type and treatment time, Tuberculosis skin test (TST)
(positive/negative) or QuantiFERON results, isoniazid prophylaxis status, concomitant
CS treatment (yes/no). For TB patients, time until TB development and organ
involvement type were also recorded.
2.2. TB screening

Patients were screened for TB before and during the TNF-α antagonist treatments according to the Consensus Report on using TNF-α antagonists endorsed by the Rheumatology Society of Turkey [6]. Before starting TNF-α antagonists, patients were evaluated for TB by a questionnaire for the presence of prior TB infection or treatment with anti-tuberculosis drugs and a history of contact with a tuberculosis-infected case. Additionally, patients were evaluated for the occurrence of TB signs and symptoms with a physical examination. At the same time, patients underwent TST or QuantiFERON test depending on the availability and Chest radiograph. If the TST result is ≥ 5mm or QuantiFERON test was positive, isoniazid (INH) prophylaxis 300 mg/day for nine months was started. In case of a suspicious finding for latent TB in the chest radiograph or in physical examination and anamnesis, INH prophylaxis was decided with a chest disease or infectious disease specialist, even if screening tests were negative. Patients were followed up every 3-6 months for the development of pulmonary or extra-pulmonary TB with symptom inquiry and physical examination. Chest radiographs were also repeated once a year. In the case of suspected TB infection during follow-up, an appropriate evaluation was made.

2.3. Statistics

Means of continuous variables and standard deviation when the data were distributed normally were calculated. Medians and first to third quartile intervals were calculated when data that did not have a normal distribution. Group differences for dependent categorical variables were analyzed with the Chi-square or Fishers’ exact test.
Continuous variables were compared with student t-test or Mann-Whitney U when data were skewed. A two-tailed p-value <0.05 was considered significant.

Study protocol was approved by Marmara University Local Ethics Committee (approval number: 09.2020.978) and the study was performed according to the Declaration of Helsinki.

3. Results

3.1. Patient demographics

A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-α antagonist for a median of 33 months (Q1:12, Q3:62). During this period, 1560 different TNF-α antagonist prescriptions were started, Etanercept (n=509, 33%) and Adalimumab (n=509, 33 %) were the most frequently selected. The most common diagnosis were AS (n= 644; 51%) and RA (n=477; 38%), respectively. Either TST or QuantiFERON tests were positive in 823 (65%) patients, and the rate of patients that used INH prophylaxis (872, 69%) was slightly more than test positivity. CS treatment data were collected in 795 patients as received/not received. Within this group, 38% of the patients received CS at any time during the follow-up period. The characteristics of all patients in the study are summarized in Table 1.

3.2. Patient characteristics with and without TB

Among 1277 patients, 13 (1%) of them developed TB during the follow-up period. While the median age of TB-positive and negative patients was similar (50 and 49
years, respectively), male presence was higher in TB-positive patients (76% vs. 24%). TST and/or QuantiFERON positivity and INH usage rates were comparable between the two groups. Although, the median time of (month) TNF-α antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p=0.47). Similarly, TB-positive patients were treated with CS more than TB-negatives (80 % vs. 60 %). The comparison of patients with and without TB is summarized in Table 1. All percentages are given based on the total number of patients with and without TB within the columns in Table 1.

Within 13 TB-positive patients, 6 of them had pulmonary, 6 had extra-pulmonary TB and 1 had both. Time from the initiation of TNF-α antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). At the time of TB diagnosis, all 13 patients were on anti-TNFα treatments (4 Etanercept, 5 Adalimumab, 2 Infliximab, and 2 Certolizumab Pegol). Due to disease activity, Certolizumab Pegol and Etanercept were started again after TB treatment for two patients with AS diagnosis.

According to the underlying disease, TB was more frequent in the AS group (n=5, 0.7%) compared to the other diseases, but patients with BD (n=3, 8.1%) had the highest rate for TB (Table 2). There was a statistically significant increase of TB development in BD patients than non-BD patients after TNF-α antagonists (7.5% vs. 0.8%, respectively, p=0.007). When we combined our patients with the other series from Turkey, among 12928 patients who received TNF-α antagonists, TB was positive in 12 (3.9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p<0.00001). A summary of all studies published from Turkey, which reported the TB
incidence after TNF-α antagonists and comparison with the present study is given in
Table 3.

3.3. Comparison of BD patients with and without Tuberculosis

Among 40 patients with BD, TB-positive patients (n=3) were all male and had a slightly
younger mean age than TB-negatives (34.6 vs. 39 years, respectively, p=0.456). All TB-
positive patients with BD used INH prophylaxis and had a positive TST / QuantiFERON. Median time (month) of TNF-α antagonist and CS treatment rates were
also slightly higher in TB-positive than TB negative patients with BD [(20 months vs 16
months, respectively, p=0.939) and (3/3 100% vs 29/33 88%, respectively, p=0.522).

4. Discussion

This study confirmed the increased risk of TB after anti-TNFα treatments and suggested
that this increased risk might be greater in BD compared to other rheumatic disorders.

TNF-α has an important role, particularly in the defense against mycobacteria and is
essential for the maintenance of granuloma formation [7]. Other key functions of TNF-
α include regulation of apoptosis, release of cytokines from activating macrophages,
and effects on the formation of nitric oxide and the leucocyte movement [8]. Increased
TB frequency after anti-TNFα treatments has been reported from large registries [9-12].
This increased risk has been reported more prominently for monoclonal antibodies
Adalimumab and Infliximab compared to soluble receptors such as Etanercept.
Although screening and prophylaxis improved much in recent years, TNF-α inhibition
may affect some countries more seriously, such as Turkey, with a not too-low (22/100
000) incidence of TB. In a multicenter cohort study from Turkey, Kıracık et al. reported 73 TB-positive cases within 7768 patients treated with TNF-α antagonists [3]. In other publications from Turkey, Çağatay et al. reported 22 TB-positive cases within 1887 patients and Börekcî et al. 16 TB-positive cases within 1964 patients after TNF-α antagonists [13, 14]. Our TB prevalence was similar to these other studies from Turkey (0.7-1.1%).

As both BD and TB infection are common diseases in Turkey, TB data among TNF-α antagonist treated patients deserve separate analysis. Apart from Turkey, a few case reports have been published in the literature on BD and TB coexistence [15-18]. In the series from Turkey, Kıracîk et al. showed that TB development rate was higher in BD compared to other rheumatic diseases (5/129, 4%). TB rate was also reported higher in BD than other diseases by Çağatay et al. (1/53, 1.8%). Börekcî et al. also found BD to be associated with the development of TB infection in multivariate analysis (3/83, 3.6%, p=0.003). We documented even a higher rate of TB among BD patients than other Turkish cohorts (3/40, 7.5%). As a whole, the more frequent use of TNF-α antagonists in recent years in patients with major organ involvement also suggested by the recent EULAR Recommendations, requires more research on the infectious side-effects of anti-TNFα treatments in BD (1).

Some underlying mechanisms may be suggested for this higher TB prevalence after anti-TNFα exposure in BD. Patients with major-organ BD are generally males at a younger age and usually actively participate in the workforce, which may cause more contact with mycobacteria compared to other patient groups. The fact that BD patients have lower socio-economic status may be another reason [4, 5]. Higher CS doses (0.5-1
mg/kg/day), especially used in the initial use of TNF-α antagonists, to suppress major
organ damage such as vision loss or arterial complications may also contribute to the
development of TB. Immune mechanisms leading to BD activation, such as augmented
innate immunity and male gender-related effects, might also predispose BD patients to
mycobacterial infections. Finally, some HLA genes are associated with tuberculosis
[19-22]. Some of these genetic associations are also shown in BD [23, 24]. More studies
are needed to clarify these mechanisms.

Our study has some limitations. Data for the concomitant use, especially dosing of CS
treatments and additional immunosuppressives, are not collected in our group. Also, we
do not formally assess the socio-economic status data of our patients.

In conclusion, our results suggest a higher frequency of TB infections in BD patients
with TNF-α antagonists. As biologic agents are increasingly used for major organ
involvement in current practice for BD, screening mechanisms should be carefully
implemented and followed.

References


to significant increase in tuberculosis risk: a multicenter active-surveillance report.


16. Yan Shen H-fM, Yan-li Yang, Jian-long Guan. Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet's disease: A case


Tables

Table 1. Characteristics of the patients treated with anti-TNF-α antagonists

<table>
<thead>
<tr>
<th></th>
<th>All patients (n=1277)</th>
<th>Patients without TB (n=1264)</th>
<th>Patients with TB (n=13)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Median (Q1-Q3), Years</td>
<td>49 (39-58)</td>
<td>49 (39-58)</td>
<td>50 (41-61)</td>
<td>0.514</td>
</tr>
<tr>
<td>Male</td>
<td>597 (47)</td>
<td>587 (46.4)</td>
<td>10 (77)</td>
<td>0.046</td>
</tr>
<tr>
<td>TST and/or QuantiFERON Positivity</td>
<td>823 (65)</td>
<td>815 (65)</td>
<td>8 (61)</td>
<td>0.530</td>
</tr>
<tr>
<td>INH Prophylaxis</td>
<td>875/1268 (69)</td>
<td>867/1255 (69)</td>
<td>8/13 (61)</td>
<td>0.556</td>
</tr>
<tr>
<td>Corticosteroid Treatment (at any time)</td>
<td>480/797 (60)</td>
<td>472/785 (60)</td>
<td>8/10 (80)</td>
<td>0.330</td>
</tr>
<tr>
<td>Anti-TNFα Treatment time median (Q1-Q3) (month)</td>
<td>33 (12-62)</td>
<td>33 (12-62)</td>
<td>48 (22-80)</td>
<td>0.470</td>
</tr>
</tbody>
</table>

Anti-TNFα Treatment

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Etanercept</td>
<td>509 (40)</td>
<td>501 (40)</td>
<td>8 (61)</td>
<td>0.153</td>
</tr>
<tr>
<td>Disease</td>
<td>Patients with TB (n)</td>
<td>Patients without TB (n)</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>----------------------</td>
<td>-------------------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>509 (40)</td>
<td>504 (40)</td>
<td>5 (38)</td>
<td>1.000</td>
</tr>
<tr>
<td>Infliximab</td>
<td>380 (30)</td>
<td>375 (30)</td>
<td>5 (38)</td>
<td>0.544</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>84 (7)</td>
<td>81 (6)</td>
<td>3 (23)</td>
<td>0.049</td>
</tr>
<tr>
<td>Golimumab</td>
<td>78 (6)</td>
<td>78 (6)</td>
<td>0</td>
<td>1.000</td>
</tr>
</tbody>
</table>

### Inflammatory Disease

<table>
<thead>
<tr>
<th>Disease</th>
<th>Patients with TB (n)</th>
<th>Patients without TB (n)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid Arthritis</td>
<td>479 (38)</td>
<td>475 (38)</td>
<td>4 (30)</td>
</tr>
<tr>
<td>Ankylosing Spondylitis</td>
<td>648 (51)</td>
<td>643 (51)</td>
<td>5 (38)</td>
</tr>
<tr>
<td>Psoriatic Arthritis</td>
<td>96 (8)</td>
<td>95 (8)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Behçet’s Disease</td>
<td>40 (3)</td>
<td>37 (3)</td>
<td>3 (23)</td>
</tr>
<tr>
<td>Takayasu’s Arteritis</td>
<td>14 (1)</td>
<td>14 (1)</td>
<td>0</td>
</tr>
</tbody>
</table>

Except where indicated otherwise, values are the number/total number (percent) of patients. TNF: tumor necrosis factor; TB: tuberculosis; TST: Tuberculosis skin test; INH: isoniazid.

* Comparison of patients with and without TB

Table 2. The frequency of TB development according to the underlying disease
Table 3. Studies comparing tuberculosis risk in Behçet’s disease to other inflammatory diseases in the published literature

<table>
<thead>
<tr>
<th></th>
<th>Börekçi et al, 2015</th>
<th>Kısaçık et al, 2016</th>
<th>Çağatay et al 2017</th>
<th>Present Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients treated with TNF-α antagonists (n)</td>
<td>1964</td>
<td>7768</td>
<td>1887</td>
<td>1277</td>
</tr>
<tr>
<td>Age years (mean ± SD)</td>
<td>39.7 ± 13.9</td>
<td>43.4 ± 13.6</td>
<td>42.41 ± 12.71</td>
<td>48.7 ± 13.2</td>
</tr>
<tr>
<td>Male/Female (n)</td>
<td>1009/955</td>
<td>3673/4095</td>
<td>907/980</td>
<td>597/680</td>
</tr>
<tr>
<td>TST/QuantiFERON positivity, n (%)</td>
<td>1162 (59)</td>
<td>4243 (54.6)</td>
<td>1127 (67.4)</td>
<td>823 (65)</td>
</tr>
<tr>
<td>INH prophylaxis n (%)</td>
<td>1250 (63.6)</td>
<td>5704 (73.4)</td>
<td>NR</td>
<td>872 (69)</td>
</tr>
<tr>
<td>Time from initiation of TNF-α antagonist treatment to the diagnosis of TB</td>
<td>mean ± SD: 26.8 ± 17.1 months (range 1–60, median 26.5)</td>
<td>IFX: 13 months (range 1–96), ADA: 13 months (range 3–36), ETN: 7 months (range 4–60)</td>
<td>mean ± SD: 25.7 ± 19.4</td>
<td>median: 40 months (Q1-Q3: 22-56)</td>
</tr>
<tr>
<td>TB positivity, n (%)</td>
<td>3/83 (3.6% Behçet's Disease 13/1881 (0.7% Other diseases)</td>
<td>5/129 (4%</td>
<td>1/53 (1.8%</td>
<td>3/40 (7.5%</td>
</tr>
</tbody>
</table>

TNF: tumor necrosis factor; TB: tuberculosis; TST: Tuberculosis skin test; INH: isoniazid; NR: Not reported; IFX: Infliximab; ADA: Adalimumab; ETN: Etanercept; SD: Standard deviation